GlassScriptPhysician profile
Ashley Jo Bostic Adams
NPI 1821357070
$4,480.47
in general payments reported to CMS, 2019-2025
34 companies · $693 in 2025
The $693 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $543 · 2020: $291 · 2021: $817 · 2022: $705 · 2023: $733 · 2024: $699 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $542.43 | 2019-2025 | |
| Abbott Laboratories | $450.96 | 2021-2025 | Cardiomems, Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $399.49 | 2019-2025 | Trintellix |
| Abbvie INC. | $360.47 | 2021-2025 | Qulipta, Vraylar |
| Lilly USA, LLC | $322.86 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $289.89 | 2021-2025 | |
| Novo Nordisk INC | $261.45 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $259.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $212.60 | 2019-2025 | Airsupra |
| Glaxosmithkline, LLC. | $194.55 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.45 | 2021-2024 | Jardiance |
| Amgen INC. | $164.98 | 2019-2025 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $122.37 | 2019-2025 | Spravato |
| Boston Scientific Corporation | $111.15 | 2021-2023 | Watchman Access System |
| Merck Sharp & Dohme LLC | $92.27 | 2019-2021 |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.